Robert S. Landsman

Array ( [id] => 18701370 [patent_doc_number] => 11787869 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-17 [patent_title] => Methods of using muscle targeting complexes to deliver an oligonucleotide to a subject having facioscapulohumeral muscular dystrophy or a disease associated with muscle weakness [patent_app_type] => utility [patent_app_number] => 17/936483 [patent_app_country] => US [patent_app_date] => 2022-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 11 [patent_no_of_words] => 34415 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 196 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17936483 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19855586 [patent_doc_number] => 12258409 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-03-25 [patent_title] => Method of assessing the efficacy of a test agent for modulating programmed death 1 (PD-1) signaling by using anti-phosphotyrosinylated PD-1 monoclonal antibodies [patent_app_type] => utility [patent_app_number] => 17/934441 [patent_app_country] => US [patent_app_date] => 2022-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 47 [patent_figures_cnt] => 60 [patent_no_of_words] => 38192 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 364 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17934441 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20193588 [patent_doc_number] => 20250270298 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-08-28 [patent_title] => MULTIVALENT ANTI-CAMPYLOBACTER ANTIBODIES AND VACCINE [patent_app_type] => utility [patent_app_number] => 18/692967 [patent_app_country] => US [patent_app_date] => 2022-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18610 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18692967 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18497472 [patent_doc_number] => 20230220113 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-13 [patent_title] => ANTI-HUMAN NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/941741 [patent_app_country] => US [patent_app_date] => 2022-09-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43823 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17941741 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18266723 [patent_doc_number] => 20230087965 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-23 [patent_title] => FUSION PROTEINS FOR SELECTIVELY DEPLETING ANTIGEN-SPECIFIC ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/930545 [patent_app_country] => US [patent_app_date] => 2022-09-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21054 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -46 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17930545 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18800075 [patent_doc_number] => 11833221 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-12-05 [patent_title] => Oligomeric compounds for reducing DMPK expression [patent_app_type] => utility [patent_app_number] => 17/823854 [patent_app_country] => US [patent_app_date] => 2022-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19758 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17823854 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19021321 [patent_doc_number] => 20240077492 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-07 [patent_title] => ARRAY-BASED PEPTIDE LIBRARIES FOR THERAPEUTIC ANTIBODY CHARACTERIZATION [patent_app_type] => utility [patent_app_number] => 17/822757 [patent_app_country] => US [patent_app_date] => 2022-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33173 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17822757 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18537553 [patent_doc_number] => 20230242651 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-03 [patent_title] => STABLE ANTIBODY VARIABLE DOMAIN FRAMEWORK COMBINATIONS [patent_app_type] => utility [patent_app_number] => 17/821199 [patent_app_country] => US [patent_app_date] => 2022-08-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22186 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 213 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17821199 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18352089 [patent_doc_number] => 20230140200 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-04 [patent_title] => COMPOSITIONS AND METHODS FOR DETECTING CELLS UNDERGOING FERROPTOSIS USING AN ANTIBODY [patent_app_type] => utility [patent_app_number] => 17/818807 [patent_app_country] => US [patent_app_date] => 2022-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24817 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17818807 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19556508 [patent_doc_number] => 20240368300 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-07 [patent_title] => ANTI-CD93 ANTIBODY [patent_app_type] => utility [patent_app_number] => 18/682907 [patent_app_country] => US [patent_app_date] => 2022-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10853 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18682907 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19990917 [patent_doc_number] => 20250129139 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-04-24 [patent_title] => CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING gD AND ONCOLYTIC VIRUSES FOR CANCER THERAPY AND TREATMENT OF HSV [patent_app_type] => utility [patent_app_number] => 18/682713 [patent_app_country] => US [patent_app_date] => 2022-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6476 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18682713 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19554926 [patent_doc_number] => 20240366718 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-07 [patent_title] => PHARMACEUTICAL COMPOSITIONS COMPRISING HLA FUSION PROTEINS [patent_app_type] => utility [patent_app_number] => 18/681073 [patent_app_country] => US [patent_app_date] => 2022-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15426 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 136 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18681073 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18024042 [patent_doc_number] => 20220375541 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-24 [patent_title] => METHODS OF TREATING A SUBJECT SUFFERING FROM RHEUMATOID ARTHRITIS WITH ALTERNATIVE TO ANTI-TNF THERAPY BASED IN PART ON A TRAINED MACHINE LEARNING CLASSIFIER [patent_app_type] => utility [patent_app_number] => 17/881441 [patent_app_country] => US [patent_app_date] => 2022-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35684 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17881441 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19389401 [patent_doc_number] => 20240279271 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-22 [patent_title] => Method To Purify An Antibody Composition Using Cation Exchange Chromatography [patent_app_type] => utility [patent_app_number] => 18/681162 [patent_app_country] => US [patent_app_date] => 2022-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3063 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 116 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18681162 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20193605 [patent_doc_number] => 20250270315 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-08-28 [patent_title] => NOVEL ANTI-SIRPA ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/292922 [patent_app_country] => US [patent_app_date] => 2022-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28753 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18292922 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19793365 [patent_doc_number] => 12234295 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-02-25 [patent_title] => Chimeric transmembrane protein comprising antibody dimerization domains and a type I cytokine receptor endodomain, encoding nucleic acids thereof and methods of use thereof [patent_app_type] => utility [patent_app_number] => 17/815110 [patent_app_country] => US [patent_app_date] => 2022-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 9 [patent_no_of_words] => 16173 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17815110 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18510104 [patent_doc_number] => 20230226205 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-20 [patent_title] => ANTI-CDH6 ANTIBODY AND ANTI-CDH6 ANTIBODY-DRUG CONJUGATE [patent_app_type] => utility [patent_app_number] => 17/874239 [patent_app_country] => US [patent_app_date] => 2022-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40183 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17874239 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19477495 [patent_doc_number] => 20240325537 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-03 [patent_title] => CELLULAR THERAPIES FOR CANCER BY INHIBITION OF MONOCARBOXYLATE TRANSPORTER 11 [patent_app_type] => utility [patent_app_number] => 18/580954 [patent_app_country] => US [patent_app_date] => 2022-07-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20243 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18580954 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18451569 [patent_doc_number] => 20230192847 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => TIGIT ANTIBODIES, ENCODING NUCLEIC ACIDS AND METHODS OF USING SAID ANTIBODIES IN VIVO [patent_app_type] => utility [patent_app_number] => 17/866303 [patent_app_country] => US [patent_app_date] => 2022-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 166714 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17866303 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19992000 [patent_doc_number] => 20250130222 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-04-24 [patent_title] => IDENTIFICATION OF COMMON TUMOR-SPECIFIC T CELL RECEPTORS AND ANTIGENS [patent_app_type] => utility [patent_app_number] => 18/579526 [patent_app_country] => US [patent_app_date] => 2022-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8885 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18579526 [rel_patent_id] =>[rel_patent_doc_number] =>)